Investing.com -- Bank of America upgraded Moderna to Neutral with a $170 price objective, following a sharp rally in the stock after positive data on its personalized cancer vaccine, intismeran, in adjuvant melanoma.
Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
144last 24h
877last 7d
147● bullish (7d)
98● bearish (7d)
214publishers
Investing.com35d agobullish
BofA upgrades Moderna after 177% rally driven by cancer vaccine breakthroughGuruFocus.com37d agobearish
Intel Stock Plunges 7% as UBS Cuts Price Target to $112Intel Stock Takes Another Hit as UBS Trims Price Target to $112